In melanoma, patients receiving pulsed DC vaccine including CD8 epitopes and helper peptides develop CTL and helper T cell responses with better clinical outcomes compared to patients vaccinated only with CD8 epitopes. The gene discussed is CD8A; the disease is melanoma.